Foscarnet for suppression of human immunodeficiency virus replication.
The effect of foscarnet against human immunodeficiency virus (HIV) was evaluated in nine HIV-infected individuals; six completed 28 days of induction therapy. The overall mean increase in CD4+ lymphocytes was 64 cells per mm3. The mean decline in the HIV antigen concentration was 108 pg/ml (P = 0.03), and suppression was related to systemic foscarnet exposure by a maximum-effect pharmacodynamic model.
Fletcher
C V
CV
Department of Pharmacy Practice, University of Minnesota, Minneapolis.
Collier
A C
AC
Rhame
F S
FS
Bennett
D
D
Para
M F
MF
Beatty
C C
CC
Jones
C E
CE
Balfour
H H
HH
D000328:Adult; D001499:Bayes Theorem; D015496:CD4-Positive T-Lymphocytes; D004311:Double-Blind Method; D005260:Female; D017245:Foscarnet / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015488:HIV Antigens / Q000032:analysis; D015658:HIV Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D014779:Virus Replication / Q000187:drug effects*
D015488:HIV Antigens; D017245:Foscarnet